YourVoice.Now
Back to Dashboard
HRES-93House2025-02-04Congress

Providing for consideration of the bill (H.R. 27) to amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes.

YourVoice.Now Summary

This resolution sets the ground rules for how the House will debate and vote on H.R. 27, a bill that would change how fentanyl-related substances are classified under federal drug law. It waives procedural objections that could otherwise block the bill from reaching the floor, adopts a committee amendment to H.R. 27 as already in effect, and limits floor debate to one hour split equally between supporters and opponents. Members would be permitted to offer one additional amendment specified by the Rules Committee, and one motion to recommit the bill is also allowed. Procedural resolutions like this one — often called 'rules' — are standard steps that set defined terms for floor consideration of a specific piece of legislation.

Congressional Summary

This resolution provides for consideration of H.R. 27, the Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act. Specifically, it waives all points of order against consideration of the bill.Under the resolution, the bill is to be considered as amended according to changes by the Rules Committee in its report accompanying the resolution.

Legislative Subjects

House of RepresentativesLegislative rules and procedure

Details

Congress
119th
Chamber
House
Status
summarized
Action
Reported to House
Action Date
2025-02-04
Date Added
2026-06-30
Source
Congress.gov →

Like reading a bill in plain English?

We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.

By default, we'll only email you once — when the app launches. Unless you opt in below, you won't receive anything else. We don't share or sell your email.